失调的BARD1通过上调CYP2C8促进卵巢癌中帕克利塔塞尔耐药性
Li Zhang1, Zixuan Pan1, Liqin Zhang2
1Gynecology Department 1, Affiliated Hospital of Shandong Second Medical University, Weifang, China.
Folia biologica
|October 30, 2025
概括
在卵巢癌 (OC) 中较低的BARD1水平与帕克利塔塞尔耐药性相关. 恢复BARD1可能会克服耐药性,为这种致命的妇科恶性瘤提供新的治疗点.
科学领域:
- 在瘤学瘤学.
- 妇科 妇科医生 妇科
- 药理学 药理学是指药理学的学科.
背景情况:
- 卵巢癌 (OC) 是妇科癌症死亡的主要原因.
- 帕克利塔克塞尔耐药性显著限制了OC中的治疗疗效和患者存活率.
- 在OC帕克利塔塞尔敏感性中BARD1的作用尚不清楚.
研究的目的:
- 调查OC中BARD1表达和帕克利塔塞尔敏感性之间的关系.
- 阐明BARD1通过哪种机制影响着帕克利塔塞尔耐药性的机制.
- 确定BARD1作为一种潜在的治疗点,用于克服OC中帕克利塔塞尔耐药性.
主要方法:
- 从帕克利塔塞尔响应者和不响应者的OC瘤样本中分析BARD1表达.
- 在BARD1和CYP2C8表达之间的相关性分析.
- 在OC细胞中BARD1的体外功能实验 (过度表达和击倒).
- 在BARD1操纵后评估帕克利塔塞尔IC50值.
主要成果:
- 与响应者相比,帕克利塔塞尔不响应者中的BARD1水平显著降低.
- 在非响应者中,CYP2C8的表达上调,与BARD1水平负相关.
- BARD1下调增加了OC细胞系中帕克利塔塞尔IC50值,表明抗性增强.
- 在帕克利塔塞尔治疗的背景下,BARD1作为瘤抑制剂起作用.
结论:
- 降低BARD1的调节有助于通过上调CYP2C8.8调节卵巢癌中帕克利塔塞尔耐药性.
- BARD1作为瘤抑制剂,其减少的表达与较差的治疗结果有关.
- 准BARD1或调节其通路是克服OC中帕克利塔塞尔耐药性的有希望的策略.
相关概念视频
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
01:15Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:31The Intrinsic Apoptotic Pathway
8.1K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.1K
02:23Abnormal Proliferation
5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K